Literature DB >> 7119510

The kidney is the main site of interferon degradation.

T Bino, Z Madar, A Gertler, H Rosenberg.   

Abstract

Male Sprague Dawley rats (300 g) were infused by constant infusion into the jugular vein through 3-5 h with human leukocyte-derived interferon (HuIFN-alpha 10(6) units/h, 0.9 ml/h). Blood samples were collected every 20 min through the carotid. A steady-state level of interferon in serum (10(4) U/ml) was reached after 50 min of infusion, indicating fast removal of most of the infused material. Examination of interferon distribution in various tissues at the termination of the infusion revealed that over 85% of active interferon was found in the kidneys. No interferon was found in urine. Ligation of both kidneys resulted (after 2.5 h of infusion) in a ten-fold increase in interferon in serum and a minor increase in other tissues. No interferon was found in the kidneys. Simultaneous infusion of HuIFN-alpha, pepstatin and leupeptin (the well-known inhibitors of lysosomal proteinases) for 2.5 h had no effect on interferon concentration in serum and various tissues except in kidneys where a 5-fold increase was found. Mitochondrial-lysosomal fractions contained 55% of the total kidney interferon. Partial inhibition of proteolytic and HuIFN-alpha degrading activities at that fraction was also observed. These data, together with our previous findings of accumulation of injected interferon in the mitochondrial-lysosomal fraction of rats and monkeys' kidney cells, provide a further evidence for the main role of the kidney in HuIFN-alpha degradation.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7119510     DOI: 10.1089/jir.1982.2.301

Source DB:  PubMed          Journal:  J Interferon Res        ISSN: 0197-8357


  9 in total

Review 1.  Clinical pharmacokinetics of interferons.

Authors:  R J Wills
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

2.  Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons.

Authors:  Leonid Kagan; Anson K Abraham; John M Harrold; Donald E Mager
Journal:  Pharm Res       Date:  2010-03-16       Impact factor: 4.200

3.  The pharmacokinetics of peginterferon lambda-1a following single dose administration to subjects with impaired renal function.

Authors:  Matthew W Hruska; Robert Adamczyk; Elizabeth Colston; Michael Hesney; Michele Stonier; Heather Myler; Richard Bertz
Journal:  Br J Clin Pharmacol       Date:  2015-07-22       Impact factor: 4.335

4.  Assessment of the antigenic response in humans to a recombinant mutant interferon beta.

Authors:  M W Konrad; A L Childs; T C Merigan; E C Borden
Journal:  J Clin Immunol       Date:  1987-09       Impact factor: 8.317

5.  Diagnosis, management, and treatment of hepatitis C: an update.

Authors:  Marc G Ghany; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

6.  Treatment of metastatic renal cell carcinoma with subcutaneous interleukin 2: evidence for non-renal clearance of cytokines.

Authors:  R E Banks; M A Forbes; S Hallam; A Jenkins; M Wadhwa; P Dilger; A Meager; R Thorpe; C J Bowmer; J K Joffe; P Patel; P W Johnson; P J Selby
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 7.  The role of interferons in the treatment of malignant neoplasms.

Authors:  J R Murren; A C Buzaid
Journal:  Yale J Biol Med       Date:  1989 May-Jun

8.  Interferon Induced Focal Segmental Glomerulosclerosis.

Authors:  Yusuf Kayar; Nuket Bayram Kayar; Nadir Alpay; Jamshid Hamdard; Iskender Ekinci; Sebnem Emegil; Rabia Bag Soydas; Birol Baysal
Journal:  Case Rep Nephrol       Date:  2016-10-26

9.  Effect of liposome-encapsulation on immunomodulating and antiviral activities of interferon-gamma 1.

Authors:  E G Saravolac; B Kournikakis; L Gorton; J P Wong
Journal:  Antiviral Res       Date:  1996-03       Impact factor: 5.970

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.